

Please add the following new claims:

A5  
--43. (New) The antagonist of claim 28, wherein the antagonist comprises about two to four polypeptides comprising a TWEAK receptor extracellular domain or fragments or variants thereof that are capable of binding TWEAK.

44. (New) The recombinant host cell of claim 33, wherein the host cell is a prokaryote selected from the group consisting of *E. coli*, *Bacillus subtilis*, and *Salmonella typhimurium*.


45. (New) A TWEAK receptor antagonist produced by the method comprising culturing the host cell of claim 33 under conditions promoting expression of the antagonist.--

#### REMARKS

The foregoing amendments do not narrow the scope of the claims and/or are made for reasons unrelated to statutory concerns. Support for the amendments can be found throughout the specification and claims as originally filed. For example, support for the amendment to claims 8 and 28 and new claim 43 can be found at page 6, line 34 to page 7, line 35. Support for new claim 44 can be found, for example, at page 11, lines 31-37.

Should the Examiner have any questions, or believes that a teleconference would be helpful to clarify or advance the present application to allowance, the Examiner is invited to call the undersigned attorney at (206) 389-4155. Please charge the additional claims fee of \$54.00 for the additional three dependent claims to the account number below. No fee (other than the additional claims fee) is believed to be due with respect to the filing of this paper. The Examiner is authorized to charge any fees or credit any overpayments to deposit account number 09-0089.

Respectfully submitted,

  
Joseph R. Baker  
Reg. No. 40,900

Immunex Corporation  
51 University Street  
Seattle, Washington 98101  
(206) 587-0430 (main)  
(206) 233-0644 (FAX)